AM 411
Alternative Names: AM-411Latest Information Update: 06 May 2024
At a glance
- Originator Altamira Therapeutics
- Class Antirheumatics; Peptides; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 01 May 2024 Altamira Therapeutics files a provisional patent application with the USPTO which covers nanoparticles comprising OligoPhore™ platform and siRNA targeting the p65 protein
- 10 Apr 2024 Altamira Therapeutics plans to file an IND application to the US FDA for Rheumatoid arthritis, in 2025
- 29 Jul 2022 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis released by Altamira Therapeutics